

## Special Issue

# The Development of SARS-CoV-2 Vaccines Using Various Strategies

### Message from the Guest Editor

SARS-CoV-2, which emerged at the end of 2019, is still rampant around the world, causing enormous health and economic damage. The development of SARS-CoV-2 vaccines has proceeded at an unprecedented pace, and several vaccines have already been approved and administered in many countries. However, despite expectations that global vaccination will lead to the end of the pandemic, variants possessing amino acid substitutions in the antigenic sites of the SARS-CoV-2 spike protein continue to emerge all over the world, raising concerns about the effectiveness of the current vaccines. Therefore, it is important to continue to develop vaccines using strategies that improve our preparedness for these emerging variants. In this Special Issue, we seek articles (both reviews and original research) discussing the development of SARS-CoV-2 vaccines using various strategies.

### Guest Editor

Dr. Tokiko Watanabe

Department of Molecular Virology Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan

### Deadline for manuscript submissions

closed (20 April 2022)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/95124](https://mdpi.com/si/95124)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).